000			02086nam a2200277 4500
001			ESSALUD
005			20260903091623.0
007			ta
008			t pe ||||| |||| 00| 0 spa d
040			_aBMG
041			_aeng
100			_aHwang, Thomas J. _eAutor _954498
245			_aReforming payment for clinician-administered drugs — Most-favored-nation pricing in medicare Part B
300			_apáginas: 1774-1777
520			_aAddressing escalating spending on prescription drugs by Medicare Part B, which covers clinician-administered drugs, has been a top U.S. policy priority. On December 19, 2025, the Trump administration announced a new payment model to align Medicare Part B fee-for-service payments for prescription drugs with international pricing benchmarks. This proposal — the Global Benchmark for Efficient Drug Pricing (GLOBE) model — was released alongside parallel most-favored-nation pricing models for Medicare Part D (Guarding U.S. Medicare against Rising Drug Costs, or GUARD) and Medicaid (Generating Cost Reductions for U.S. Medicaid, or GENEROUS). These announcements followed a May 2025 executive order calling for most-favored-nation pricing and previous efforts by the Obama administration and the first Trump administration to control Part B spending. If implemented, the GLOBE model could reduce costs for Medicare beneficiaries, taxpayers, and the Medicare program. But exceptions could limit participation in the model, and, in the absence of safeguards, its provisions could alter incentives for innovation.
650			_aALERGIA _97055
650			_aINMUNOLOGÍA GENERAL _953664
650			_aEFICACIA COMPARATIVA _954499
650			_aCOSTO DE LA ATENCIÓN MÉDICA _954150
650			_aMEDICAMENTOS, DISPOSITIVOS Y LA FDA _954223
650			_aPOLÍTICA SANITARIA INTERNACIONAL _954131
700			_aClemans-Cope, Lisa _954500
700			_aKesselheim, Aaron S. _954501
773	0		_022717 _922676 _dMassachusetts NEJM Group _oNEJM015 _tThe New England Journal of Medicine _wESSALUD _x0028-4793
942			_cARTICULOS _e2026-08-31 _zsqb
999			_c22912 _d22912